The Antiplatelet Agent Pletaal (Nonproprietary Name: Cilostazol) The Results of CSPS 2, a Large-Scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Posted on the Online Version of The Lancet Neurology®

Tokyo, Japan -- Otsuka Pharmaceutical Co., Ltd. today announced that the results of CSPS 2, a large-scale clinical trial of cilostazol (Product Name: Pletaal) in preventing recurrent strokes, were posted on the online version of The Lancet Neurology, a British major medical journal in neurology, on September 11, 2010.* CSPS 2: Cilostazol Stroke Prevention Study 2*

The release as fetched from its publisher. otsuka.co.jp ↗